NeuroCatalyst Commercialization Fund Administrator

ESD intends to establish a $45M NeuroCatalyst Commercialization Fund as part of its Bolstering Biotech Initiative to accelerate development and commercialization of life science research and innovations that address neurodegenerative diseases (ND), such as Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Motor Neuron Disease, Huntington’s Disease, Amyotrophic Lateral Sclerosis and others. The NeuroCatalyst Commercialization Fund (the “Fund”) is modeled after the successful Biodefense Commercialization Fund launched by the Life Science Initiative in 2021. ESD is seeking competitive proposals for a qualified third-party firm (“Respondent”) to assist in the implementation of this Fund. The Services to be performed will include, but are not limited to, overall hosting and management of application development, distribution, and processing; information sessions, outreach to and communications with prospective applicants and awardees; establishing an as-needed mentor program for grantees; identification and management of Expert Reviewers and Mentors; marketing the Fund; website and/or webcopy development and upkeep; and communications and outreach about the Fund to key stakeholders. Business enterprises awarded an identical or substantially similar procurement contract within the past five years: none Service-Disabled Veteran-Owned Business (SDVOB) SDVOB Goal: 6.00% Minority / Women Business Enterprise contracting goals (MWBE) MBE Goal: 15.00% WBE Goal: 15.00%